🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

2) We are thrilled to welcome back expert author Sid Patel MD Sid M. Patel #Cardiologist @HarvardMed TIMI Study Group. Sid helped lead the #AZALEA #TIMI-71 trial & presented some of the data we'll be discussing here, along with other data presented by Samer Alsaid.

17) Also at #ACC25, Samer Alsaid of TIMI Study Group presented an analysis of the #AZALEA study by age. Now recall pts enrolled in the trial were at least 55 & the median age was 74. And we know older age is a strong #riskfactor for 🩸with currently available #anticoagulants.

Dr. Benjamin Scirica co-chairs the session, "Bringing Logic to the Madness of Evaluating Chest Pain in ED and Outpatient Clinic", tomorrow at 2:30pm in S403A #ACC25

Analysis of >74,000 pts from 5 multinational CV outcome trials shows circulating galectin-3 to have strong association with heart failure, kidney function decline, and CV death, suggesting a potential role in cardiorenal risk assessment Stephen Wiviott Robert Giugliano David Berg #ACC25

Earlier vs later initiation of #evolocumab leads to a significantly lower rate of complex coronary revascularization procedures (complex PCI and CABG) up to 8 years of follow-up. Robert Giugliano #ACC25

From #ACC25: In patients with #AFib, #abelacimab, compared with #rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. American College of Cardiology JACC Journals TIMI Study Group Sid M. Patel Robert Giugliano thecardiologyadvisor.com/reports/abelac…

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. André Zimerman @bweber04 ana laura kunzler @rgiuglaino ahajournals.org/doi/full/10.11…

Does the CV benefit of evolocumab differ in patients with autoimmune or inflammatory diseases? The answer lies at the intersection of dyslipidemia and inflammation. A 🧵 on our new Circulation paper. (1/10) Link: ahajournals.org/doi/abs/10.116… TIMI Study Group Robert Giugliano

Coverage in NEJM Journal Watch of André Zimerman's analysis of #evolocumab in patients in FOURIER TIMI 59 with autoimmune or inflammatory disease. Robert Giugliano jwatch.org/na58726/2025/0…

Beyond the❤️: GLP-1 RAs also reduce non-CV mortality. Meta-analysis of 11 CVOTs (n=90,867) shows ↓ in all-cause, CV, and non-CV deaths in people with T2DM/obesity. Yumi Kang, MD, PhD, MPH dom-pubs.onlinelibrary.wiley.com/doi/abs/10.111…

Update on MCS for AMI-shock reviews various options and latest data. Robert Giugliano link.springer.com/article/10.100…

Essence – TIMI 73b met its primary endpoint with olezarsen, an ASO targeting APOC3, robustly reducing levels of triglycerides! Look forward to sharing more details at an upcoming scientific congress. Brian Bergmark

BWH highlighting our recent NEJM publication of AZALEA-TIMI 71 trial demonstrating the substantially lower bleeding with the FXI inhibitor #abelacimab compared with rivaroxaban in AF patients. brighamhealthonamission.org/2025/05/21/fac…

FOURIER OLE complex revasc analysis highlighted in the European Society of Cardiology Journals Cardiovascular Pharmacotherapy ACC.25 summary academic.oup.com/ehjcvp/advance…